Listeria monocytogenes is the second or third most common cause of neonatal sepsis and meningitis (1). This short grampositive motile rod is thought to be pathogenic by virtue of its ability to survive intracellularly (2). Resistance to Listeria infection appears to be mediated by IFN-a/,6 and IFN-7, which induce increased macrophage, lymphocyte, and natural killer cell activity in vivo and improve survival among pretreated Listeriainfected animals (3-12). Some investigators, however, have questioned the direct effect of IFN, suggesting instead that its role may be to enhance the activities of other lymphokines (13, 14) . Despite this controversy, the effect of IFN pretreatment acting either directly or indirectly on Listeria-infected animals seems well established. (12). Because neonatal listeriosis has high mortality despite aggressive antibiotic treatment, we investigated the possibility that IFN might have an adjunctive therapeutic role. Here, we report the results of these studies using a newborn animal model. In contrast to our earlier studies in which IFN had a beneficial effect when given before infection, we found no improvement in animal survival or in bacterial load if animals were treated with IFN after infection was established.
IFN, interferon rRIFN-y, recombinant rat interferon-y CFU, colony forming units i.p., intraperitoneal(1y) LAM, lipoarabinomannan or LDgO, 25% and 90% lethal dose, respectively
Listeria monocytogenes is the second or third most common cause of neonatal sepsis and meningitis (1). This short grampositive motile rod is thought to be pathogenic by virtue of its ability to survive intracellularly (2) . Resistance to Listeria infection appears to be mediated by IFN-a/,6 and IFN-7, which induce increased macrophage, lymphocyte, and natural killer cell activity in vivo and improve survival among pretreated Listeriainfected animals (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Some investigators, however, have questioned the direct effect of IFN, suggesting instead that its role may be to enhance the activities of other lymphokines (13, 14) . Despite this controversy, the effect of IFN pretreatment acting either directly or indirectly on Listeria-infected animals seems well established. (12) . Because neonatal listeriosis has high mortality despite aggressive antibiotic treatment, we investigated the possibility that IFN might have an adjunctive therapeutic role. Here, we report the results of these studies using a newborn animal model. In contrast to our earlier studies in which IFN had a beneficial effect when given before infection, we found no improvement in animal survival or in bacterial load if animals were treated with IFN after infection was established.
MATERIALS AND METHODS
Reagents. Rat IFN-CY/P was purchased from Lee Biophysics, San Diego, CA. rRIFN-y is the product of transfection with a plasmid carrying the chromosomal rat IFN-y gene as described elsewhere (20) . IFN-a/@ and rRIFN-y were diluted in pyrogen free sterile PBS containing 0.1 % albumin to a concentration of lo5 U/mL of stock solution. Lipopolysaccharide was not detectable in rRIFN-r (<1.0 ng/mL) and was present in low concentration in IFN-(r/$ (-10 n g / m~) .
A strain of L. monocytogenes type 4b (designated 15U previously) isolated originally from the blood of an infant with early onset neonatal sepsis was used in these studies (2 1, 22) . Aliquots of a stock culture were stored in 20% glycerol and frozen at -20°C until required for animal studies. A portion of the frozen aliquot was inoculated into brain heart infusion broth (BHI; Difco Laboratories, Detroit, MI) and incubated at 37°C overnight. The organism was sedimented (3000 x g for 10 min) and washed once in PBS. The number of bacteria were estimated spectrophotometrically and confirmed for each experiment using the pour plate technique. Minimal inhibitory concentration of ampicillin against the organism as determined by serial dilution was 0.46 pg/mL. The minimal bactericidal concentration was 3.20 pg/mL (22) . parturition (usually on the 2 1st or 22nd d of gestation).
For studies in which animals were pretreated with IFN, rat pups were injected i.p. with PBS or lo5 U/kg of IFN-a/@ or rRIFN-y at 48 and 24 h before i.p. challenge with L. monocytogenes [1.0 + 0.5 x lo5 CFU (mean + SEM) per animal] which was given on d 3 of life. This inoculation was equivalent to approximately LD,, in this schedule of injections. In these experiments, animals were killed by CO, inhalation 3 d after bacterial challenge. The spleen was dissected free, weighed, and homogenized in PBS. Duplicate pour plates were prepared using serial dilutions in sterile water from the splenic homogenates and bacterial content expressed as CFU/100 mg of spleen. In all experiments, animals were returned to their mother when not being treated.
In studies in which animals were treated with IFN after bacterial challenge, 3-d-old rats were injected i.p. with 1.0 f 0.5 X 1 Oh CFU for survival experiments or 1.8 + 0.1 x 10' CFU for dissection experiments (LD93 and LDZ5, respectively, in this experimental protocol). Forty-eight and 72 h later, they were injected s. Statistical analysis. Analysis of groups was done using a twosided paired t test for comparison of concentration of bacteria in tissue. A X 2 test with Yates correction was used to compare survival of various groups (23) .
RESULTS
In preliminary experiments, we found no improvement in survival or in bacterial content of spleen when newborn animals were injected with Listeria followed later by treatment with IFNa/@. This was despite the fact that IFN-a/@ was 100% protective when administered before infection at this dose (12) . Inasmuch as in this animal model most deaths occurred at or before the 3rd d of infection, we reasoned that no effect was evident because insufficient time had elapsed for IFN to act. We therefore modified the model by treating with antibiotics to prolong survival. A subcurative dose of ampicillin (20 mg/kg/d) was deliberately chosen because we wished to assess the potential additive effects of IFN.
As shown in Figure 1 , survival of Listeria-infected animals was better ( p < 0.05 on d 4 after challenge) if they were treated with ampicillin 48 and 72 h after bacterial challenge. However, addition of IFN-a/@ or rRIFN-y to therapy did not improve survival any further for these animals. For all ampicillin-treated animals, including IFN-a/@, rRIFN-y, and placebo groups, medial survival was approximately 4 d. We next considered the possibility that the inoculum of bacteria (approximately LDgo) was too high to demonstrate any potential benefit of IFN. In a second experiment, bacterial challenge of animals was lowered to 1.8 X lo5 CFU (approximately L D 4 . As shown in Table 1 , bacterial content of spleen in Listeria-infected ampicillin-treated animals was not improved by treatment with two doses of 10' U/Kg of IFN-c(/P or rRIFN-y or a combination of these two IFN. In these experiments, bacterial load was lower ( p < 0.05 two-sided t test) for control animals that were not treated with IFN compared with groups of animals treated with IFN-alp, rRIFN-y, or IFN-a/P plus rRIFN-7.
In contrast to this, newborn rats treated with IFN-a/P, rRIFNy , or IFN-a/@ plus rRIFN-y before bacterial challenge had decreased ( p < 0.05) bacterial concentration in the spleen (Table   2 ). In this experiment the bacterial inoculum was lower than in the first experiment and antibiotics were not given. The inoculum was approximately equivalent to a LD15 under these conditions. In addition, it is noteworthy that a single inoculation of rRIFNy produced lower bacterial loads only if it was preceded by IFNa/@ and not by PBS.
DISCUSSION
L. monocytogenes is an intracellular pathogen that resides chiefly within the cells of the mononuclear phagocytic system. Although the underlying defect in newborn immunity to L. monocytogenes is not clearly understood, the failure of the macrophage to kill or inhibit the organism is a central factor. The macrophage has been shown to alter its metabolic, phagocytic, and bactericidal activity when stimulated by macrophage activating factor or recombinant IFN-y (24) . Several investigators have studied the role of IFN-y in L. monocytogenes infection. In 1984, Kiderlen et al. (6) demonstrated that IFN-y pretreatment of mice led to their increased resistance to killing by L. monocytogenes. We and others have shown similar results using a newborn rat model of L. monocytogenes infection (1 2, 25) .
These observations led us to speculate that IFN-y or IFN-a/P may have a potential therapeutic role in established infection. In the present experiments we examined this possibility. To our surprise, we showed no benefit of rRIFN-y or IFN-a/B when given by themselves or in combination with ampicillin to Listeria-infected newborn rats. This conclusion was drawn after studies on animal survival and bacterial load in spleens. In fact, use of IFN after bacterial challenge increased bacterial load in spleens. In contrast, the same dose of IFN given before bacterial challenge had an opposite effect. Bacterial load in the spleen was significantly decreased by pretreatment with two injections of rRIFN-y. In addition, we have demonstrated here that a single injection with rRIFN-y was effective in limiting growth of Listeria in the spleen if animals were pretreated with IFN-a/P even though IFN-a//3 by itself had no effect, suggesting that IFN-alp may prepare the host for response to IFN-y.
The overall conclusion from the experiments is that IFN modifies host response to L. monocytogenes infection differently if it is given after rather than before infection. The explanation for such an apparent paradox is at present unknown. Several explanations for these observations should be considered; products manufactured by the bacteria or products made by the host after infection may modify host responsiveness to cytokine. Alternatively, the sequence of cytokine appearance may be a critical factor.
That some organisms may produce exotoxins in vivo that render cells unresponsive to IFN has been shown for Mycobacterium leprae (26) . Macrophages from animals infected with M. leprae are defective in their responsiveness to lymphokines including IFN-y even though these cells appear to be normal in other functions. The inhibiting effect of M. leprae is due to a major cell wall constituent, LAM, which specifically inhibits efferent functions of mouse macrophages. Preincubation with LAM resulting in uptake of LAM into cytoplasmic vacuoles of macrophages was necessary to show inhibition (26) . No such product has been identified for L. monocytogenes. A second possibility is that a product secreted by the host may be induced during L. monocytogenes infection that renders the macrophages unresponsive. Such a macrophage deactivation protein, which blocks activation by IFN-7 and reverses preexisting activation, has been identified from tumor cell lines (27) . Finally, the possibility that the sequence of IFN appearance is crucial should be considered. Indeed, both an agonist and an antagonist effect of IFN-a/@ has been demonstrated on activation of human macrophages depending on the time of introduction and concentration of this IFN in vitro (28) . Others have described a synergistic interaction between IFN on transcription of IFN-stimulating genes only when the sequence of IFN introduction was controlled (29) .
Although our observations should not be generalized to other animal species or infections, we believe that the therapeutic potential of IFN should be critically evaluated in similar models before clinical trials of it in such circumstances are undertaken.
